Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced that it will host an investor ...

Current Board’s Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 MonthsNew Leadership is ...

The Company has also granted to the underwriter a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price per share, less underwriter discounts and ...

The billionaire’s aggressive efficiency drive has critics warning of a constitutional crisis. Allies say he’s just getting started ...

The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceutica ...

Village Medical is reportedly in talks with Banner Health weeks after Walgreens confirmed plans to sell the primary care provider, an email shows.

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Gil Roth, President of the Pharma & Biopharma Outsourcing Association, shared his insights in the CPHI Annual Report 2024, ...